Oct 29, 5:08 PM ET
AptarGroup reported third-quarter 2026 sales up 6% to $1.02 billion, but reported diluted EPS fell to $0.51 from $1.92 after a $61.2 million pre-tax loss tied to deconsolidating its Russian subsidiary. Adjusted EPS was $1.52, down from $1.62 a year earlier, and the company guided fourth-quarter adjusted EPS to $1.39 to $1.47 while raising its quarterly dividend to $0.50 from $0.48.
- Reported sales rose 6% to $1.02 billion; core sales rose 5% in the quarter.
- Reported diluted EPS was $0.51 versus $1.92 a year earlier; the Russia deconsolidation cost $0.94 per diluted share after tax.
- Adjusted EPS was $1.52 versus $1.62 in the prior year period; Q4 2026 adjusted EPS guidance is $1.39 to $1.47.
- Board approved a quarterly dividend increase from $0.48 to $0.50, payable December 3, 2026; Q3 buybacks totaled about 234 thousand shares for $30 million.
Read the filing on SEC.gov ↗
Sep 10, 4:06 PM ET
AptarGroup's Chief Accounting Officer, Aditya Gandhi, resigned effective September 11, 2026, to pursue another opportunity outside the greater Chicago area, and the company said the decision was not related to any disagreement on operations, policies or practices. The Board appointed Daniel Ackerman, a former CAO, as interim Chief Accounting Officer and principal accounting officer until a permanent successor is named.
- Aditya J. Gandhi resigns as Vice President, Chief Accounting Officer, effective September 11, 2026
- Daniel Ackerman, age 53, appointed Senior Vice President, Interim Chief Accounting Officer, effective September 11, 2026
- Ackerman previously served as CAO from August 1, 2024 until June 8, 2026, and has been SVP, Finance for Aptar Pharma since June 2026
- Ackerman will report to Vanessa Kanu, Executive Vice President and Chief Financial Officer
Read the filing on SEC.gov ↗
Sep 1, 6:06 AM ET
AptarGroup expanded its board from ten to eleven directors and appointed Gael Touya as a director effective September 1, 2026. Touya also became President and Chief Executive Officer that day, succeeding Stephan B. Tanda, who retired; the CEO change was previously disclosed in a March 17, 2026 filing. For shareholders, this filing confirms the leadership transition and board addition, with no financial results or guidance included.
- Gael Touya appointed director effective September 1, 2026, with term expiring at the 2028 annual meeting.
- Board size increased from ten to eleven directors on August 29, 2026.
- Touya, formerly President of the Aptar Pharma segment, became CEO on September 1, 2026, succeeding Stephan B. Tanda.
- Touya will not receive additional pay for board service; CEO compensation was disclosed in the March 17, 2026 8-K.
Read the filing on SEC.gov ↗
Jul 30, 5:19 PM ET
AptarGroup reported second quarter 2026 reported sales up 6% to $1.03 billion, the first quarter above $1 billion, but reported diluted EPS fell to $1.36 from $1.67 a year earlier, and adjusted EPS fell to $1.42 from $1.68. The company expects third quarter adjusted EPS of $1.45 to $1.53, and CEO Stephan Tanda will hand over to Gael Touya on September 1, 2026.
- Reported sales rose 6% to $1.03 billion; core sales rose 1%.
- Reported diluted EPS was $1.36 versus $1.67; adjusted EPS was $1.42 versus $1.68.
- Adjusted EBITDA margin was 20.7% versus 22.6% in the prior year quarter.
- Q3 2026 adjusted EPS guidance is $1.45 to $1.53; Gael Touya becomes CEO on September 1, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
